Previsioni
Il prezzo obiettivo medio degli analisti è 37,98 € (-10,42%). La mediana è 35,54 € (-16,18%).
| Acquista |
Â
7 |
| Mantieni |
Â
13 |
| Vendi |
Â
1 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
CONMED: growth accelerates due to AirSeal, BioBrace and international expansion
CONMED reports at the Wells Fargo conference an accelerated growth dynamic and expects 2026 revenue growth of 5–6% with a pickup to 6–8% in the second half of the year. Drivers are the products AirSeal, BioBrace and Buffalo Filter as well as increasing internationalization, which now accounts for 45% of revenue. Management sees margin expansion of 50–100 basis points, improved free cash flow conversion through inventory and working-capital optimization, and plans selective acquisitions while prioritizing debt reduction. » Altro su de.investing.com
CONMED Corporation considers sale – shares jump more than 8% after Bloomberg report
CONMED Corporation’s shares rose more than 8 percent in Friday after-hours trading after Bloomberg reported that the medical-technology company was weighing a possible sale. According to the report, CONMED is evaluating its options after takeover interest was expressed. » Altro su de.investing.com
CONMED appoints John E. Gallagher as CFO effective July 15, 2026
CONMED has appointed John E. Gallagher as its new chief financial officer; he will assume the role on July 15, 2026. Gallagher succeeds Todd Garner, who will remain with the company in an advisory capacity until November 2, 2026. Gallagher brings about 30 years of financial and industry experience, most recently as CFO of Certara and previously of Cue Health, along with extensive leadership experience at Becton, Dickinson & Co. » Altro su de.investing.com
Conmed stock falls to 52-week low at $32.1
Conmed shares hit a 52-week low of $32.1 and are down about 37.92% year-to-date. Despite the price decline, the company is rated as having a "GOOD" financial score and is valued at a P/E ratio of 18.27; InvestingPro classifies the stock as significantly undervalued. Conmed beat Q1 2026 analyst expectations for EPS ($0.89 vs. $0.82) and revenue ($317 million) and secured a $450 million term-loan facility to repay convertible bonds. Management repurchased shares, and the board will be expanded on July 1, 2026, with the additions of Celine Martin and Jeff Mirviss. » Altro su de.investing.com
CONMED raises organic growth, gastroenterology exit weighs on revenue
CONMED beat adjusted EPS expectations for Q1 2026 with $0.89 and reported total revenue of $317.0 million, with reported growth pressured by the withdrawal from the gastroenterology business and currency effects. Adjusted for the divestiture of the GI business, organic growth at constant exchange rates was 2.1%, while the divestiture caused a 5.1 percentage-point headwind. Orthopedic surgery showed strong momentum with $147.7 million and +4.5% currency‑adjusted growth, while domestic revenue declined. CONMED raised its organic full-year growth outlook to 5.0–6.5%, kept the adjusted EPS target at $4.30–4.45, and emphasized portfolio focus and supply‑chain transformation; the stock nevertheless fell in after‑hours trading. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2025, CONMED Co. ha già distribuito 0,71 € di dividendi. L'ultimo pagamento è avvenuto a ottobre 2025.
Dati finanziari
Nell'ultimo trimestre, CONMED Co. ha registrato ricavi pari a 296,25 Mln € e un utile netto di 17,48 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 296,25Â Mln | 2,68% |
| Utile lordo | 166,99Â Mln | 24,06% |
| Utile netto | 17,48Â Mln | 617,37% |
| EBITDA | 49,73Â Mln | 91,42% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,26 Mld € |
Numero di azioni | 29,8Â Mln |
Massimo/minimo a 52 settimane | 49,94 € - 28,65 € |
| Dividendi | No |
Beta | 0,90 |
Rapporto P/E | 19,24 |
Rapporto PEG | 1,10 |
Rapporto P/B | 1,31 |
Rapporto P/S | 1,01 |
Profilo aziendale
CONMED Corporation, un'azienda di tecnologia medica, sviluppa, produce e vende dispositivi chirurgici e attrezzature correlate per procedure chirurgiche in tutto il mondo. Offre prodotti per la chirurgia ortopedica, tra cui TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors e PopLok Knotless Suture Anchors, che forniscono soluzioni cliniche uniche ai chirurghi ortopedici per la riparazione di lesioni dei tessuti molli, nonché prodotti di supporto che consentono ai chirurghi di eseguire interventi di medicina sportiva mininvasivi. L'azienda commercializza i prodotti per la chirurgia ortopedica con i marchi Hall, CONMED Linvatec, Concept e Shutt. Offre inoltre prodotti per la chirurgia generale, come prodotti clinici per l'insufflazione, l'evacuazione dei fumi, l'elettrochirurgia ed endomeccanici; e tecnologie endoscopiche, tra cui prodotti diagnostici e terapeutici per l'uso in procedure di gastroenterologia e prodotti per il trattamento delle malattie delle strutture biliari, nonché prodotti per il monitoraggio cardiaco comprendenti elettrodi per ECG ed EEG e piastre per la defibrillazione cardiaca. L'azienda commercializza i propri prodotti direttamente presso ospedali, centri chirurgici e altre strutture sanitarie, nonché tramite distributori specializzati nel settore medico. CONMED Corporation è stata fondata nel 1970 e ha sede a Largo, in Florida.
| Nome | CONMED Co. |
| CEO | Patrick J. Beyer |
| Sede centrale | Largo,
fl Stati Uniti |
| Sito web | |
| Settore | SanitĂ |
| Industria | Tecnologia sanitaria |
| Quotazione in borsa | 23/07/1987 |
| Dipendenti | 3900 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | CNMD |
Frankfurt | EC8.F |
DĂĽsseldorf | EC8.DU |
SIX | EC8.SW |
MĂĽnchen | EC8.MU |